1.28
1.28 (0%)
As of Oct 15, 2024
Seelos Therapeutics, Inc. [SEEL]
Source:
Company Overview
We are a clinical-stage biopharmaceutical company focusedon achieving efficient development of products that address significant unmet needs in Central Nervous System (“CNS”) disordersand other rare disorders.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | (646) 293-2100 |
| Industry | manufacturing |
| CEO | Raj Mehra, Ph.D. |
| Website | http://www.seelostherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.4 |
| Operating Profit | $-3.1 |
| Net Income | $1.7 |
| Net Cash | $-2.7 |
Profit Ratios
| Gross Margin | $0.4 |
| Operating Margin | -834.8 |
| Profit as % of Revenues | 22% |
| Profit as % of Assets | 124.1% |
| Profit as % of Stockholder Equity | -6.1% |
Management Effectiveness
| Return on Equity | -6.1% |
| Return on Assets | 71.8% |
| Turnover Ratio | 27.3% |
| EBITA | $-3.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $2.4 |
| Total Liabilities | $30.5 |
| Operating Cash Flow | $-5.6 |
| Investing Cash Flow | |
| Financing Cash Flow | $2.9 |
